Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Inclusion Criteria: * Have fully understood the study and voluntarily signed the informed consent; * 18-75 years old (including 18 and 75 years old); * Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma; * No previous anti-tumor treatment for metastatic diseases; * HER2 positive; * Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; * Life expectancy ≥ 3 months; * At least one measurable lesion according to RECIST version 1.1; * The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment): * Absolute neutrophil count ≥1.5×109/L; * Platelet ≥100×109 /L; * Hemoglobin ≥90g/L; * Total bilirubin \< 1.5 ULN; * ALT and/or AST \< 1.5 ULN ; * Serum creatinine (Cr) \<1.5×ULN; * Endogenous creatinine clearance ≥50ml/min; * Female patients of childbearing age should take effective contraceptive measures; * Good compliance, cooperate with follow-up. Exclusion Criteria: * Failure to comply with the study protocol or study procedure; * Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors; * Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix; * Known presence of symptomatic central nervous system metastasis or brain metastases; * Had aut…